Zhejiang Medicine Co., Ltd. (SHA:600216)
China flag China · Delayed Price · Currency is CNY
12.68
-0.03 (-0.24%)
Sep 4, 2026, 3:00 PM CST

Zhejiang Medicine Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
8,8988,8349,3367,7628,0739,088
Other Revenue
46.2346.2338.7632.1143.2341.3
8,9448,8819,3757,7948,1169,129
Revenue Growth
-3.75%-5.28%20.29%-3.96%-11.10%24.60%
Cost of Revenue
6,1405,9845,5915,3925,4385,530
Gross Profit
2,8042,8963,7852,4022,6783,599
Selling, General & Admin
1,4501,4091,6781,4811,3121,546
Research & Development
512.83579.88749.35860.07809.28806.86
Other Operating Expenses
43.2451.3753.8552.369.8675.17
Operating Expenses
2,0032,0372,4942,3942,1882,439
Operating Income
801.3859.521,2917.98489.741,160
Interest Expense
-24.82-24.82-26.37-28.34-33.11-39.54
Interest & Investment Income
62.232.7222.5116.5113.1857.42
Currency Exchange Gain (Loss)
74.9774.9717.8236.5966.6-64.31
Other Non Operating Income (Expenses)
-190.77-5.23.921.09-36.73-2.69
EBT Excluding Unusual Items
722.89937.21,30853.83499.671,111
Impairment of Goodwill
---18.68-9.23-8.12-
Gain (Loss) on Sale of Investments
25.914.64-29.6-28.59-56.5151.73
Gain (Loss) on Sale of Assets
-6.72-6.56-5.21323.57-1.37-7.95
Asset Writedown
28.42-25.62-69.41---46.19
Other Unusual Items
42.0742.0726.7723.6957.7144.76
Pretax Income
812.56951.731,212363.28491.391,154
Income Tax Expense
161.33191.49192.0386.48128.77268.97
Earnings From Continuing Operations
651.23760.241,020276.79362.61884.56
Minority Interest in Earnings
154.86113.14140.26152.85176.96160.76
Net Income
806.09873.381,161429.64539.571,045
Net Income to Common
806.09873.381,161429.64539.571,045
Net Income Growth
-46.91%-24.74%170.11%-20.37%-48.38%45.71%
Shares Outstanding (Basic)
955955959955964959
Shares Outstanding (Diluted)
955955959955964959
Shares Change
-0.75%-0.42%0.46%-0.91%0.47%0.26%
EPS (Basic)
0.840.911.210.450.561.09
EPS (Diluted)
0.840.911.210.450.561.09
EPS Growth
-46.80%-24.79%168.89%-19.64%-48.62%45.33%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,0301,439534.15-162.56-455.39197.05
Free Cash Flow Per Share
1.081.510.56-0.17-0.470.20
Dividend Per Share
0.2800.2800.3700.1500.1700.330
Dividend Growth
-24.32%-24.32%146.67%-11.77%-48.48%43.48%
Gross Margin
31.35%32.61%40.37%30.82%33.00%39.43%
Operating Margin
8.96%9.68%13.77%0.10%6.03%12.71%
Profit Margin
9.01%9.84%12.38%5.51%6.65%11.45%
Free Cash Flow Margin
11.52%16.21%5.70%-2.09%-5.61%2.16%
EBITDA
1,4811,5692,013732.171,1711,747
EBITDA Margin
16.56%17.67%21.47%9.39%14.42%19.14%
D&A For EBITDA
680.08709.85721.94724.19680.81586.79
EBIT
801.3859.521,2917.98489.741,160
EBIT Margin
8.96%9.68%13.77%0.10%6.03%12.71%
Effective Tax Rate
19.85%20.12%15.84%23.81%26.21%23.32%
Revenue as Reported
8,8818,8819,3757,7948,1169,129
Advertising Expenses
-9.4518.4621.2519.5921.3